A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)
The MS Center at EvergreenHealth is conducting an open-label study in subjects with Relapsing Multiple Sclerosis (RMS) treated with ozanimod HCl.
Who may be eligible to participate?
Male or female patients, age 18 to 65 years (inclusive) who have been diagnosed with RMS within 5 years of Screening. Other inclusion/exclusion criteria apply.
What does participation involve?
All subjects will receive orally administered ozanimod HCl 1 mg. Subjects must have been diagnosed with RMS within 5 years of study entry. The treatment period is 36 months. For subjects who discontinue the study, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit.
Virginia I. Simnad, MD, MSc, EvergreenHealth MS Center